Mehmet Ali EREN, Timuçin AYDOĞAN, Mehmet Emin DEMİR, Melih PAMUKCU, Turgay ULAŞ

Hepatosteatozu olan metabolik sendromlu hastaların ultrasonografi ile değerlendirilmesi

Amaç: Metabolik sendrom (MetS)’lu hastalarda hepatosteatoz sıklığı tam olarak bilinmemektedir, ayrıca MetS’lu hastaların izleminde ve değerlendirilmesinde kabul görmüş etkin, basit ve ucuz bir yöntem yoktur. Çalışmamızda, MetS’lu hastalarda hepatosteatoz sıklığını ve karaci- ğer ultrasonografi (USG)’si ile saptanmış steatoz varlığı ve derecesinin MetS’lu hastaların değerlendirilmesinde ek yarar sağlayıp sağlayamayacağını ortaya koymayı amaçladık.Yöntemler: Yüz on iki MetS’lu hasta bu çalışmaya dâhil edildi. Hastalar karaciğer USG’sine göre; steatozu olmayan (kontrol, n=36), grade I steatozu olan (Grup 1, n=43), ve grade II steatozu olan (Grup 2, n=33) 3 gruba ayrıldı. Hepatosteatoz varlığı ve derecesi ile MetS parametreleri arasındaki ilişki bakıldı. Bulgular: Çalışmamızda MetS’lu hastalarda hepatosteatoz sıklığı %69,94 olarak saptandı. Kontrol grubu ve grup 1 arasında açlık insülini, HOMA-IR, AST, ALT ve GGT farklıydı (hepsi için p

Ultrasound evaluation of metabolic syndrome patients with hepatosteatosis

Objective: The exact incidence of hepatosteatosis in patients with metabolic syndrome (MetS) is unknown; also there is no valid, simple and inexpensive method to evaluate and follow-up for patients with MetS. In our study, we aimed-to demonstrate the frequency of hepatosteatosis, and wheth- er demonstrate presence and degree of steatosis using liver ultrasonography may provide additional benefit for evaluating and following-up in MetS patients with non-alcoholic fatty liver disease. Methods: One hundred and twelve patients with MetS were included to the study. Patients divided into three groups; control group (n= 36) consisted of patients without hepatosteato- sis, group 1 (n=43) consisted of patients with grade 1 hep- atosteatosis. Finally, group 2 (n= 33) consisted of patients with grade 2 hepatosteatosis. The relationship between the presence and degree of the hepatosteatosis and MetS parameters were analyzed. Results: The incidence of hepatosteatosis was found 69.4% in patients with MetS. There were significantly differences in HOMA-IR, AST, ALT and GGT levels among control group and group 1 (p

PDF

___

1. Arslan M. [Metabolic Syndrome: Diagnosis, pathogen- esis, diagnostic criteria and components]. Türkiye Klinikleri J Int Med Sci 2006;2:1-7.
2. Karşıdağ K. [Management Principles of Metabolic Syn- drome]. Türkiye Klinikleri J-Endocrin-Special Topics 2011;4:62-66.
3. Amasyalı E, Kılıçlı F, Acıbucu F, et al. [Association be- tween nonalcoholic fatty liver disease and hs-CRP in patients with metabolic syndrome]. Cumhuriyet Tıp Derg 2010;32:26-33.
4. Shi HB, Fu JF, Liang L, Wang et al. Prevalence of nonalcoholic fatty liver disease and metabolic syndrome in obese children. Zhonghua Er Ke Za Zhi 2009;47:114-118.
5. Alberti KG, Zimmet PZ. Definition, diagnosis and clas- sification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mel- litus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
6. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein choles- terol in plasma, without use of the preparative ultra- centrifuge. Clin Chem 1972;18:499-502.
7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
8. Onat A, Sansoy V. [Metabolic Syndrome, Major Cul- prit of Coronary Disease Among Turks: Its Prevalence and Impact on Coronary Risk]. Türk Kardiyol Dern Arş 2002;30:8-15.
9. Kozan O, Oguz A, Abaci A, et al. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 2007;61:548-553.
10. Velligan DI, Castillo D, Lopez L, et al. A Case Control Study of the Implementation of Change Model Versus Passive Dissemination of Practice Guidelines for Compliance in Monitoring for Metabolic Syndrome. Community Ment Health J 2012;doi:10.1007/s10597- 011-9472-z.
11. Levenson H, Greensite F, Hoefs J, et al. Fatty infiltration of the liver: quantification with phase-contrast MR imaging at 1.5 T vs biopsy. AJR Am J Roentgenol 1991;156:307-312.
12. Pilleul F, Chave G, Dumortier J, et al. Fatty infiltration of the liver. Detection and grading using dual T1 gradient echo sequences on clinical MR system. Gastroenterol Clin Biol 2005;29:1143-1147.
13. Kotronen A, Westerbacka J, Bergholm R, et al. Liv- er fat in the metabolic syndrome. J Clin Endocrinol Metab 2007;92:3490-3497.
14. Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode exami- nation in the diagnosis of liver steatosis. Dig Liver Dis 2006;38:485-489.
15. Hamaguchi M, Kojima T, Takeda N, et al. The meta- bolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-728.
16. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007;102:2708- 2715.
17. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
18. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-379.
19. Rogowski O, Shapira I, Bassat OK, et al. Waist circum- ference as the predominant contributor to the micro- inflammatory response in the metabolic syndrome: a cross sectional study. J Inflamm (Lond) 2010;7:35.
20. Steene-Johannessen J, Kolle E, Reseland JE, et al. Waist circumference is related to low-grade inflamma- tion in youth. Int J Pediatr Obes 2010;5:313-319.